Brief: Oncolytics Biotech® Presents Preclinical Data On Pelareorep-Based Combination Therapies At AACR Annual Meeting
12/04/2021 12:31
April 12 (Reuters) - Oncolytics Biotech Inc ONC.TO :
* ONCOLYTICS BIOTECH® PRESENTS PRECLINICAL DATA ON
PELAREOREP-BASED COMBINATION THERAPIES AT AACR ANNUAL MEETING
* ONCOLYTICS BIOTECH INC - PELAREOREP SYNERGIZES WITH A
BROAD
ARRAY OF ANTI-CANCER AGENTS
* ONCOLYTICS BIOTECH INC - PELAREOREP ENHANCES ANTI-TUMOR
EFFICACY
OF PARP-1 AND CDK 4/6 INHIBITORS IN PRECLINICAL MODELS
Source text for Eikon: ID:nPnbg3NlGa
Further company coverage: ONC.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Oncolytics Biotech
See all newsBrief: Oncolytics Biotech Files For Mixed Shelf Offering Of Up To $150 Million
Brief: Oncolytics Biotech® Announces Voluntary Delisting From The Toronto Stock Exchange
Advisory: Alert on global oncology breakthroughs tagged to multiple pharma firms withdrawn
Brief: Oncolytics Biotech® Appoints Former Ambrx Executive As Chief Business Officer
Brief: Oncolytics Biotech Appoints Former Ambrx Executive As Chief Business Officer